Oseltamivir availability and prescription requirements
Pro Research Analysisby 
Searched over 200M research papers
Oseltamivir Availability: Prescription and Non-Prescription Models
Oseltamivir, commonly known as Tamiflu, is an antiviral medication used to treat and prevent influenza. Its availability and prescription requirements vary by country and have evolved over time in response to public health needs and safety concerns.
Non-Prescription Oseltamivir: The New Zealand Experience
New Zealand was the first country to allow oseltamivir to be supplied without a prescription, starting in 2007. Pharmacists could provide the medication directly to consumers under strict criteria designed to balance public health benefits with safety risks. Most pharmacists viewed this non-prescription model positively and were able to apply the rules successfully, though some found the rules difficult to remember or frustrating. The supply was not driven by commercial interests, and inappropriate requests were manageable. However, the strict rules sometimes limited consumer access, and pharmacists tended to be conservative in recommending the medicine. Tools like manufacturer-supplied protocols and consultation records were valued aids for pharmacists in ensuring proper supply .
Over five years, pharmacist-supplied oseltamivir accounted for a modest proportion of total supplies, with most still dispensed by prescription. During the 2009–2010 influenza pandemic, pharmacist supply made up only 11% of total oseltamivir provision. Importantly, this non-prescription availability did not lead to increased resistance, significant stockpiling, or a decline in influenza vaccination rates. Supplies generally matched community influenza activity, and stockpiling by consumers was not a major issue .
Prescription Requirements and Adherence to Guidelines
In most countries, oseltamivir remains a prescription-only medication. Studies from France and the Netherlands show that prescription rates can be suboptimal, with many eligible patients not receiving the drug, and some prescriptions issued outside of recommended guidelines. In France, only about 60% of confirmed influenza cases received oseltamivir, with lower rates among adults and those with risk factors for severe influenza. Early administration (within 24–48 hours of symptom onset) was associated with better outcomes, but there is a need to promote appropriate use, especially in high-risk groups .
In the Netherlands, during the 2009 pandemic, about one-third of oseltamivir prescriptions did not meet national guideline criteria. Higher-educated patients were more likely to receive off-guideline prescriptions, possibly due to being more informed or assertive. Some prescriptions were not used, suggesting stockpiling, though this did not lead to shortages. The study highlighted the importance of clear, up-to-date guidelines and effective communication to ensure appropriate prescribing .
Trends in Oseltamivir Prescription and Safety
Prescription trends show that oseltamivir is often the most commonly prescribed antiviral for respiratory infections, especially in older adults and those with lower respiratory tract infections. Studies in hospital settings have found high compliance with updated protocols, especially when pharmacists are involved in validating prescriptions. Pharmaceutical interventions, such as adjusting dosages for renal impairment or correcting treatment duration, were frequently accepted and improved patient safety Davis2023Bonastre2020.
In Japan, lifting age restrictions on oseltamivir prescriptions for pediatric patients led to a significant increase in use among those aged 10–19 years, but did not result in an increase in adverse drug reactions, including abnormal behavior .
Stockpiling and Resistance Concerns
Concerns about personal stockpiling of oseltamivir have arisen during pandemic threats. In the United States and Europe, spikes in prescriptions during periods of low influenza activity suggested stockpiling behavior, particularly in response to pandemic fears. However, studies found no association between increased oseltamivir use and the emergence of resistant influenza strains in Europe Kramarz2009Ortiz2008. In New Zealand, non-prescription availability did not lead to significant stockpiling or resistance issues .
Conclusion
Oseltamivir is primarily available by prescription, with some exceptions like New Zealand's pharmacist-supply model under strict criteria. While non-prescription availability can improve access without increasing resistance or stockpiling, strict rules and clear protocols are essential. Adherence to prescribing guidelines remains a challenge in many settings, highlighting the need for ongoing education and support for both prescribers and pharmacists. Overall, careful management of oseltamivir availability and prescription practices can optimize public health benefits while minimizing risks.
Sources and full results
Most relevant research papers on this topic
Is non-prescription oseltamivir availability under strict criteria workable? A qualitative study in New Zealand.
Pharmacists in New Zealand welcome non-prescription oseltamivir, but strict rules for supply frustrate them and limit potential public health benefits.
Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling
Non-prescription oseltamivir in New Zealand has not significantly changed resistance development or influenza immunization rates, and pharmacist supply has not led to significant consumer stockpiling.
Adherence to Oseltamivir Guidelines during Influenza Pandemic, the Netherlands
Oseltamivir prescriptions during the pandemic were mainly given to patients with influenza symptoms and risk factors, but a significant number of patients did not meet guideline criteria.
5PSQ-034 Evaluation of oseltamivir use in clinical practice in a second level hospital
The updated oseltamivir hospital protocol in our hospital was more than 80% compliant, with over 90% of pharmaceutical interventions accepted, resulting in a safer and more optimized prescription for influenza A patients.
Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.
Oseltamivir use in European countries between 2002 and 2007 was not statistically associated with the emergence and persistence of oseltamivir-resistant influenza A(H1N1) viruses.
DOI